Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 18/20 | 0.66 |
| ▸ | DRD2 | P14416 | 3/20 | 0.66 |
| ▸ | HTR1A | P08908 | 2/20 | 0.66 |
| ▸ | HTR2A | P28223 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5203339 | 0.87 | HTR6 (0.59) | HTR6DRD2HTR1AHTR2ADRD3 | |
| SCHEMBL5200861 | 0.86 | HTR6 (0.58) | HTR6DRD2HTR1AHTR2ADRD3 | |
| SCHEMBL27506464 | 0.85 | HTR6 (0.56) | HTR6DRD2HTR1AHTR2ADRD3 | |
| SCHEMBL5202033 | 0.85 | HTR6 (0.66) | HTR6DRD2HTR1AHTR2ADRD3 | |
| Hydrochloric Acid SCHEMBL5201694 | 0.84 | HTR6 (0.65) | HTR6DRD2HTR1AHTR2ADRD3 | |
| SCHEMBL6786913 | 0.81 | HTR6 (0.52) | HTR6DRD2HTR1AHTR2AMEN1 | |
| SCHEMBL5202415 | 0.81 | HTR6 (0.52) | HTR6DRD2HTR1AHTR2A | |
| SCHEMBL4675288 | 0.80 | HTR6 (1.00) | HTR6DRD2HTR1AHTR2ACYP3A4 | |
| SCHEMBL5201804 | 0.78 | HTR6 (0.56) | HTR6DRD2HTR1AHTR2ADRD3 | |
| SCHEMBL4310106 | 0.76 | HTR6 (0.91) | HTR6DRD2HTR1AHTR2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1587788-B9 | 2,7-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | HOFFMANN LA ROCHE (CH) | 2007-10-24 | — | — | EP | claimed |
| US-7247651-B2 | 2,7-substituted indoles | ROCHE PALO ALTO LLC (US) | 2007-07-24 | — | — | US | claimed |
| EP-1587788-B1 | 2,7-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | HOFFMANN LA ROCHE (CH) | 2007-05-16 | — | — | EP | claimed |
| CN-1314669-C | 2,7-substituted indoles and their use as 5-HT6 modulators | HOFFMANN LA ROCHE (CH) | 2007-05-09 | — | — | CN | claimed |
| EP-1401813-B1 | NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | HOFFMANN LA ROCHE (CH) | 2007-02-07 | — | — | EP | claimed |
| CN-1257892-C | New indole derivatives with 5-HT6 receptor affinity | HOFFMANN LA ROCHE (CH) | 2006-05-31 | — | — | CN | claimed |
| EP-1587788-A1 | 2,7-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-26 | — | — | EP | claimed |
| CN-1681782-A | 2, 7-substituted indoles and their use as 5-HT 6 modulators | HOFFMANN LA ROCHE (CH) | 2005-10-12 | — | — | CN | claimed |
| CN-1527816-A | Novel indole derivatives having 5-HT 6 receptor affinity | - | 2004-09-08 | — | — | CN | claimed |
| US-6787535-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; PARKINSON'S DISEASE, HUNTINGTON'S DISEASE; PSYCOLOGICAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-09-07 | — | — | US | claimed |
| US-20040063724-A1 | Neurotransmitter 5-hydroxytryptamine-6 (5-HT6) antagonists | ROCHE PALO ALTO LLC | 2004-04-01 | — | — | US | claimed |
| WO-2004026830-A1 | 2,7-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | claimed |
| US-20030073700-A1 | New indole derivatives with 5HT6 receptor affinity | SYNTEX (U.S.A.) LLC, NAME CHANGE TO ROCHE PALO ALTO LLC | 2003-04-17 | — | — | US | claimed |
| EP-1587788-B9 | 2,7-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | HOFFMANN LA ROCHE (CH) | 2007-10-24 | — | — | EP | disclosed |
| US-7247651-B2 | 2,7-substituted indoles | ROCHE PALO ALTO LLC (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1587788-B1 | 2,7-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | HOFFMANN LA ROCHE (CH) | 2007-05-16 | — | — | EP | disclosed |
| US-20040063724-A1 | Neurotransmitter 5-hydroxytryptamine-6 (5-HT6) antagonists | ROCHE PALO ALTO LLC | 2004-04-01 | — | — | US | disclosed |
| EP-1401813-A1 | NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. Hoffman-la Roche AG (CH) | 2004-03-31 | — | — | EP | disclosed |
| US-20030073700-A1 | New indole derivatives with 5HT6 receptor affinity | SYNTEX (U.S.A.) LLC, NAME CHANGE TO ROCHE PALO ALTO LLC | 2003-04-17 | — | — | US | disclosed |
| WO-2002098857-A1 | NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063724-A1 | Neurotransmitter 5-hydroxytryptamine-6 (5-HT6) antagonists | HTR6, HTR5A, HTR1A | HTR6 1/4885DRD2 59/4885HTR1A 3/4885 |
| US-20030073700-A1 | New indole derivatives with 5HT6 receptor affinity | HTR6, HTR5A, HTR7 | HTR6 1/4885DRD2 36/4885HTR1A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.